Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. Am J Hematol 1995 May;49(1):92-4

Date

05/01/1995

Pubmed ID

7741147

DOI

10.1002/ajh.2830490117

Scopus ID

2-s2.0-0029015187 (requires institutional sign-in at Scopus site)   7 Citations

Abstract

This report summarizes safety and efficacy information among patients treated with high doses (> 75 U/kg) of a monoclonal antibody-purified factor IX concentrate [coagulation factor IX (human) monoclonal antibody purified)] in two clinical trials. One hundred infusions of this factor IX concentrate at doses > 75 U/kg were administered to 35 patients, six of whom had experienced thrombotic complications during previous treatment with prothrombin complex concentrate. Hemostasis in all patients was rated as "excellent," and there were no thrombotic complications.

Author List

Warrier I, Kasper CK, White GC 2nd, Shapiro AD, Bergman GE

Author

Gilbert C. White MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Antibodies, Monoclonal
Dose-Response Relationship, Drug
Factor IX
Hemostasis
Humans
Thrombosis